Showing 2261-2270 of 2314 results for "".
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft
- Unsafe Ocular Stem Cell Treatments Prevalenthttps://modernod.com/news/unsafe-ocular-stem-cell-treatments-prevalent/2479976/Experimental stem cell therapies for eye conditions are being offered at dozens of unregulated clinics in the United States, and some of these procedures are harmful, researchers report. Clinicians should warn their patients against
- Practice-Hospital Consolidation Increasing for Many Specialtieshttps://modernod.com/news/practice-hospital-consolidation-increasing-for-many-specialties/2480021/The level of integration of certain primary care practices into health systems and hospitals more than doubled in recent years, with steeper increases seen in the fields of oncology and cardiology, according to research publish
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Neuro-Optometric Rehabilitation Association (NORA) Launches Redesigned Website; Accepts Award Nominationshttps://modernod.com/news/neuro-optometric-rehabilitation-association-nora-launches-redesigned-website-accepts-award-nominations/2480061/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the launch of its redesigned website and new domain name, www.noravisionrehab.org, dedicated to educating patients, caregivers, and health care professionals about neurolog
- Zeiss Unveils Visulas Green Photocoagulation Laser at WOChttps://modernod.com/news/zeiss-unveils-next-generation-of-ophthalmic-laser-visulas-green-at-world-ophthalmology-congress/2480074/Zeiss unveiled its next-generation Visulas green photocoagulation laser at the World Ophthalmology Congress in Barcelona. Visulas green offers uninterrupted workflow by giving doctors the ability to monitor treatment settings directly from the eyepiece and the abi
- NuSight Medical Launches NuLids for the Treatment of Dry Eyehttps://modernod.com/news/nusight-medical-launches-nulids-for-the-treatment-of-dry-eye/2480078/NuSight Medical has introduced The NuLids System, a doctor-prescribed, home-use medical device that efficiently treats dry eye by gently stimulating, de-capping, and rejuvenating the meibomian glands to a healthier state. The system was introduced at the American Optometric Association mee
- Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticalshttps://modernod.com/news/nicox-announces-research-collaboration-on-novel-ophthalmic-therapeutics-with-ironwood-pharmaceuticals/2480117/Nicox SA announced its entry into a research collaboration with Ironwood Pharmaceuticals focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new
- Trump Says Drug Companies to Unveil Price Cuts in Two Weekshttps://modernod.com/news/trump-says-drug-companies-to-unveil-price-cuts-in-two-weeks/2480129/Major pharmaceutical companies will announce “voluntary, massive” cuts in drug prices in two weeks, President Donald Trump said Wednesday, without providing details, according to a
- ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/thrombogenics-enrolls-first-patient-in-phase-1-clinical-study-evaluating-thr-149-for-treatment-of-dme/2480139/ThromboGenics NV announced that it has successfully enrolled the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898). THR-149 is a novel plasma kallikrein inhibitor generated using Bicycle Therapeu